© Reuters. Senseonics vs. Tandem: Which Diabetes Stock is a Better Buy?
Given the rising number of people with diabetes, medical technology and devices that help diabetics live healthier lives are in great demand. Senseonics (SENS) and Tandem (TNDM) are two companies that focus on the treatment of diabetes. Which one of these stocks is a better buy now?.The healthcare space is considered as a recession-proof industry as people rarely delay medical expenses. Most governments are also looking to prioritize healthcare spending making this sector even more relevant.
Further, the demand for diabetes products continues to rise as cases are spiraling upwards all over the world. According to a report from the World Health Organization, around 422 million worldwide have diabetes and this disease accounts for 1.6 million deaths each year.
Keeping these factors in mind, today I’m going to analyze two diabetes stocks, Senseonics (SENS) and Tandem Diabetes Care (NASDAQ:), to try and determine which stock is a better buy.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.